SBIR/STTR Research Award

Novel Circulating RNA-based Markers as Diagnostic Biomarkers of Infectious Diseases

Award identifier f7cb1b0186d792c3da0842eb6a0b2d6c5544a566c8480cbbbf7c0dba6950249aAwarding agency Department of Defense · Office for Chemical and Biological Defense

Award amount

$149,947

Program and phase

STTR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Office for Chemical and Biological Defense
Recipient company
CFD Research Corporation
Proposal award date
2018-09-19
Contract end date
2019-03-28
UEI
V3KCP1HNFM33
Solicitation number
2018.0
Topic code
CBD18A-001

Research abstract

In resource limited settings, rapid and accurate diagnosis of infections is critical for managing potential exposures to highly virulent pathogens,whether occurring from an act of bioterrorism or a natural event. This is especially important for hard to detect intracellular bacterial andalphavirus infections, that overlap symptomatically and often treated empirically due to a lack of reliable and rapid diagnostics.We propose to undertake a systematic study to identify and validate the circulatory RNAs and the potential exosomal-based biomarkers ofVEEV infection using mouse models. Multiple clinical matrices (urine, blood, CSF, lymph) and infection routes (intranasal, subcutaneous) will bestudied to analyze the RNA biomarker dynamics in a specified diagnostic window (0-14 days, post infection). Exosome contents (e.g., miRNA)and other host-based biomarkers will also be analyzed and compared for specificity and sensitivity. Finally, we will integrate the animaloutcome in computational models to predict viral kinetics, translation of findings from animals to humans, and to make predictions ofprognostic factors for treatment efficacy and the risk of relapse and progression. Ultimately, we envision to develop a low cost, in vitrodiagnostic device for rapid and sensitive detection of pre-symptomatic, symptomatic or convalescent biomarkers of these infectious diseases.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

947 SBIR/STTR records share this UEI (1987–2026). Reported award amounts total $350,893,199. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Health and Human Services, National Science Foundation, Department of Commerce, Department of Energy

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.